Michael Binks

1.7k total citations
29 papers, 941 citations indexed

About

Michael Binks is a scholar working on Molecular Biology, Rheumatology and Oncology. According to data from OpenAlex, Michael Binks has authored 29 papers receiving a total of 941 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 11 papers in Rheumatology and 8 papers in Oncology. Recurrent topics in Michael Binks's work include Muscle Physiology and Disorders (10 papers), Rheumatoid Arthritis Research and Therapies (9 papers) and Systemic Lupus Erythematosus Research (7 papers). Michael Binks is often cited by papers focused on Muscle Physiology and Disorders (10 papers), Rheumatoid Arthritis Research and Therapies (9 papers) and Systemic Lupus Erythematosus Research (7 papers). Michael Binks collaborates with scholars based in United Kingdom, United States and Netherlands. Michael Binks's co-authors include Marion C. Dickson, Anthony G. Wilson, Ιωάννα Μαρίνου, David Moore, Devesh Mewar, Inmaculada Rioja, Mohammed Akil, Catriona Sharp, D. S. Montgomery and Sylvester Pawlak and has published in prestigious journals such as Nature Medicine, Annals of the Rheumatic Diseases and Clinical Pharmacology & Therapeutics.

In The Last Decade

Michael Binks

29 papers receiving 922 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Binks United Kingdom	18	392	250	246	169	110	29	941
Seung Cheol Shim South Korea	24	586 1.5×	386 1.5×	591 2.4×	195 1.2×	41 0.4×	100	1.5k
Zhuochun Huang China	16	323 0.8×	334 1.3×	434 1.8×	124 0.7×	20 0.2×	54	1.0k
Ronan Mullan Ireland	20	496 1.3×	401 1.6×	480 2.0×	213 1.3×	22 0.2×	43	1.2k
Nobuya Yoshida United States	22	555 1.4×	301 1.2×	964 3.9×	204 1.2×	38 0.3×	38	1.4k
Claudia de Toma France	11	403 1.0×	255 1.0×	121 0.5×	99 0.6×	29 0.3×	18	1.2k
Jiro Yamana Japan	14	237 0.6×	417 1.7×	449 1.8×	153 0.9×	25 0.2×	17	1.0k
Lianjie Shi China	15	232 0.6×	216 0.9×	425 1.7×	109 0.6×	23 0.2×	42	790
Xiaoping Qing United States	15	390 1.0×	237 0.9×	540 2.2×	217 1.3×	27 0.2×	23	1.1k
Tsan‐Teng Ou Taiwan	16	344 0.9×	246 1.0×	409 1.7×	164 1.0×	15 0.1×	59	997
Toshihiro Fukushima Japan	20	229 0.6×	299 1.2×	157 0.6×	382 2.3×	134 1.2×	77	1.1k

Countries citing papers authored by Michael Binks

Since Specialization

Citations

This map shows the geographic impact of Michael Binks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Binks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Binks more than expected).

Fields of papers citing papers by Michael Binks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Binks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Binks. The network helps show where Michael Binks may publish in the future.

Co-authorship network of co-authors of Michael Binks

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Binks. A scholar is included among the top collaborators of Michael Binks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Binks. Michael Binks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Butterfield, Russell J., Perry B. Shieh, Huihua Li, et al.. (2025). AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trial. Nature Medicine. 31(8). 2712–2721. 3 indexed citations

Sherlock, Sarah P., David Lévy, Perry B. Shieh, et al.. (2025). Cardiac safety of fordadistrogene movaparvovec gene therapy in Duchenne muscular dystrophy: Initial observations from a phase 1b trial. Molecular Therapy. 33(9). 4216–4225. 3 indexed citations

Byrne, Barry J., Russell J. Butterfield, Perry B. Shieh, et al.. (2025). Complement activation in a phase Ib study of fordadistrogene movaparvovec for Duchenne muscular dystrophy. Molecular Therapy. 33(9). 4226–4238. 1 indexed citations

Singh, Ravi Shankar Prasad, Sima S. Toussi, Frances Hackman, et al.. (2022). Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir. Clinical Pharmacology & Therapeutics. 112(1). 101–111. 90 indexed citations

Toussi, Sima S., Joel M. Neutel, J. Navarro, et al.. (2022). Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID‐19, in Subjects With Renal Impairment. Clinical Pharmacology & Therapeutics. 112(4). 892–900. 41 indexed citations

Farrokhi, Vahid, Jason Walsh, Joe Palandra, et al.. (2021). Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy. Gene Therapy. 29(10-11). 608–615. 17 indexed citations

Aartsma‐Rus, Annemieke, Jennifer E. Morgan, Hendrik Neubert, et al.. (2019). Report of a TREAT-NMD/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology. Journal of Neuromuscular Diseases. 6(1). 147–159. 44 indexed citations

Bhattacharya, Indranil, Sylvester Pawlak, Shannon Marraffino, et al.. (2017). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Domagrozumab (PF‐06252616), an Antimyostatin Monoclonal Antibody, in Healthy Subjects. Clinical Pharmacology in Drug Development. 7(5). 484–497. 42 indexed citations

Kahl, Lesley, Jessal J. Patel, Mark Layton, et al.. (2016). Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus. Lupus. 25(13). 1420–1430. 52 indexed citations

10.

Dickson, Marion C., et al.. (2015). A model of skin inflammation in humans leads to a rapid and reproducible increase in the interferon response signature: a potential translational model for drug development. Inflammation Research. 64(3-4). 171–183. 9 indexed citations

11.

Lukey, Pauline T., Shuying Yang, Simon Parry, et al.. (2012). Single doses of p38 MAP kinase inhibitors or prednisolone affect CRP and IL-6 in patients with active Rheumatoid Arthritis (RA). 2(3). 85–97. 9 indexed citations

12.

Larché, Maggie, Adrian Lim, Robert J. Eckersley, et al.. (2010). Quantitative Power Doppler Ultrasonography Is a Sensitive Measure of Metacarpophalangeal Joint Synovial Vascularity in Rheumatoid Arthritis and Declines Significantly Following a 2-week Course of Oral Low-dose Corticosteroids. The Journal of Rheumatology. 37(12). 2493–2501. 25 indexed citations

13.

Rioja, Inmaculada, Catriona Sharp, Mohammed Akil, et al.. (2008). Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor α, tumor necrosis factor receptor superfamily member 9, and macrophage colony‐stimulating factor. Arthritis & Rheumatism. 58(8). 2257–2267. 111 indexed citations

14.

Priest, Richard, John R. Spaull, Jacky B. Buckton, et al.. (2008). Immunomodulatory activity of a methionine aminopeptidase-2 inhibitor on B cell differentiation. Clinical & Experimental Immunology. 155(3). 514–522. 12 indexed citations

15.

Bansal, Aruna T., et al.. (2008). Genetic association of the major histocompatibility complex with rheumatoid arthritis implicates two non‐DRB1 loci. Arthritis & Rheumatism. 60(1). 53–62. 58 indexed citations

16.

Bainbridge, John, Leigh A. Madden, David W. Essex, et al.. (2007). Methionine aminopeptidase-2 blockade reduces chronic collagen-induced arthritis: potential role for angiogenesis inhibition. Arthritis Research & Therapy. 9(6). R127–R127. 25 indexed citations

17.

Μαρίνου, Ιωάννα, Jasmine Healy, Devesh Mewar, et al.. (2007). Association of interleukin‐6 and interleukin‐10 genotypes with radiographic damage in rheumatoid arthritis is dependent on autoantibody status. Arthritis & Rheumatism. 56(8). 2549–2556. 73 indexed citations

18.

Μαρίνου, Ιωάννα, Douglas S. Montgomery, Marion C. Dickson, et al.. (2007). The interferon induced with helicase domain 1 A946T polymorphism is not associated with rheumatoid arthritis. Arthritis Research & Therapy. 9(2). R40–R40. 26 indexed citations

19.

Mewar, Devesh, Ιωάννα Μαρίνου, David Moore, et al.. (2007). Association between radiographic severity of rheumatoid arthritis and shared epitope alleles: differing mechanisms of susceptibility and protection. Annals of the Rheumatic Diseases. 67(7). 980–983. 31 indexed citations

20.

Mewar, Devesh, David Moore, Ιωάννα Μαρίνου, et al.. (2006). Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis Research & Therapy. 8(4). R128–R128. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact